Recursion Pharmaceuticals (RXRX) expanded its partnership with Citeline to improve its AI-enabled ClinTech platform, Citeline said Tuesday.
Under the deal, Citeline's multi modal datasets will be integrated with Recursion's end-to-end platform to support clinical trial design, site selection and development decision-making, the company said.
Financial terms of the partnership were not disclosed.
Recursion Pharmaceuticals shares were more than 4% higher in Tuesday trading.
Price: 2.97, Change: +0.13, Percent Change: +4.58
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments